Oakworth Capital’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-659
| Closed | -$128K | – | 634 |
|
|
2024
Q3 | $128K | Hold |
659
| – | – | 0.01% | 253 |
|
|
2024
Q2 | $153K | Hold |
659
| – | – | 0.01% | 226 |
|
|
2024
Q1 | $142K | Hold |
659
| – | – | 0.01% | 221 |
|
|
2023
Q4 | $171K | Hold |
659
| – | – | 0.01% | 207 |
|
|
2023
Q3 | $169K | Hold |
659
| – | – | 0.02% | 182 |
|
|
2023
Q2 | $188K | Hold |
659
| – | – | 0.02% | 176 |
|
|
2023
Q1 | $183K | Hold |
659
| – | – | 0.02% | 173 |
|
|
2022
Q4 | $182K | Hold |
659
| – | – | 0.02% | 166 |
|
|
2022
Q3 | $176K | Hold |
659
| – | – | 0.02% | 167 |
|
|
2022
Q2 | $134K | Buy |
+659
| New | +$135K | 0.01% | 199 |
|
|
2021
Q2 | – | Sell |
-765
| Closed | -$214K | – | 580 |
|
|
2021
Q1 | $214K | Hold |
765
| – | – | 0.02% | 163 |
|
|
2020
Q4 | $187K | Hold |
765
| – | – | 0.02% | 165 |
|
|
2020
Q3 | $217K | Sell |
765
-3
| -0.4% | -$837 | 0.04% | 144 |
|
|
2020
Q2 | $205K | Sell |
768
-295
| -28% | -$88.7K | 0.04% | 141 |
|
|
2020
Q1 | $336K | Sell |
1,063
-52
| -5% | -$15.8K | 0.08% | 91 |
|
|
2019
Q4 | $326K | Sell |
1,115
-37
| -3% | -$10.3K | 0.06% | 115 |
|
|
2019
Q3 | $268K | Sell |
1,152
-128
| -10% | -$29.8K | 0.05% | 126 |
|
|
2019
Q2 | $299K | Buy |
1,280
+131
| +11% | +$30.2K | 0.06% | 127 |
|
|
2019
Q1 | $272K | Sell |
1,149
-15
| -1% | -$4.72K | 0.06% | 135 |
|
|
2018
Q4 | $350K | Buy |
1,164
+713
| +158% | +$228K | 0.08% | 105 |
|
|
2018
Q3 | $159K | Buy |
+451
| New | +$155K | 0.03% | 182 |
|
|
2017
Q4 | – | Sell |
-9
| Closed | -$3K | – | 626 |
|
|
2017
Q3 | $3K | Hold |
9
| – | – | ﹤0.01% | 557 |
|
|
2017
Q2 | $2K | Hold |
9
| – | – | ﹤0.01% | 567 |
|
|
2017
Q1 | $2K | Hold |
9
| – | – | ﹤0.01% | 572 |
|
|
2016
Q4 | $3K | Hold |
9
| – | – | ﹤0.01% | 554 |
|
|
2016
Q3 | $3K | Hold |
9
| – | – | ﹤0.01% | 532 |
|
|
2016
Q2 | $3K | Hold |
9
| – | – | ﹤0.01% | 509 |
|
|
2016
Q1 | $2K | Hold |
9
| – | – | ﹤0.01% | 489 |
|
|
2015
Q4 | $3K | Buy |
+9
| New | +$2.59K | ﹤0.01% | 443 |
|
Other funds holding BIIB
Oakworth Capital's BIIB Position: Q4 2024 in Review
Oakworth Capital sold out of Biogen (BIIB) in Q4 2024, closing a stake of 659 shares — an estimated $128K sold.
Oakworth Capital first reported a position in BIIB in Q4 2015 and held it in 29 quarters. The position peaked at $350K in Q4 2018. 874 funds tracked by Wall St. Rank hold BIIB as of Q4 2024.
- Oakworth Capital reported no remaining Biogen position as of Q4 2024 after selling out during the quarter.
- Oakworth Capital sold 659 Biogen shares in Q4 2024, an estimated $128K.
- Oakworth Capital first reported a position in Biogen in Q4 2015 and held it in 29 quarters.
- Oakworth Capital's Biogen position peaked at $350K in Q4 2018.
- 874 funds tracked by Wall St. Rank held Biogen as of Q4 2024.
Based on Oakworth Capital's 13F filing for Q4 2024, filed 27 Jan 2025.